Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Bromazolam molecular structure

    Bromazolam Stats & Data

    Brom Bromaz Xli-268 xli268
    NPS DataHub
    MW353.22
    FormulaC17H13BrN4
    CAS71368-80-4
    IUPAC8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
    SMILESBrc1ccc2c(c1)C(=NCc1nnc(C)n12)c1ccccc1
    InChIKeyKCEIOBKDDQAYCM-UHFFFAOYSA-N
    Benzodiazepines
    Chemical Class Triazolobenzodiazepine
    Psychoactive Class Depressant

    Receptor Profile

    Receptor Actions

    Agonists
    non-subtype selective GABAA receptor agonist with binding affinity of 2.81 nM at α1, 0.69 nM at α2, and 0.62 nM at α5 subunits
    Modulators
    Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)

    History & Culture

    Bromazolam was first synthesized in 1976 as part of benzodiazepine research, representing a structural modification of alprazolam where the chlorine atom is replaced with bromine. Despite its early synthesis, the compound was never developed as a pharmaceutical product or brought to market for medical use. The substance remained largely obscure until it emerged in the designer drug market decades later. In 2016, bromazolam was definitively identified by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) after appearing in Sweden, marking its entry into the novel psychoactive substances landscape. Since then, it has become one of the more prevalent novel benzodiazepines in circulation. In parts of North America, particularly Canada, bromazolam has become intertwined with the illicit opioid supply. Street-level products combining bromazolam with opioids such as heroin or fentanyl analogues have emerged, sometimes referred to colloquially as "benzo-dope." This adulteration pattern has raised significant public health concerns due to the compounded risks of combining central nervous system depressants.

    Effect Profile

    Curated + 3 Reports
    Benzodiazepine 7.1

    Strong anxiolysis and euphoria with strong cognitive impairment, mild sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    10
    Euphoria / Mood Lift×1
    10
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki

    No tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.

    How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.

    Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder

    Cross-Tolerances

    Alprazolam
    Diazepam
    Clonazepam
    Lorazepam
    Etizolam
    Clonazolam
    Flualprazolam
    Flubromazolam

    Experience Report Analysis

    Erowid
    4 Reports
    3 Single-substance
    2022–2024 Date Range
    4 With Age Data
    1 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 4 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 3 of 4
    • Not Specified 1 of 4

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 3 experience reports (3 single-substance Erowid)

    3 Reports
    1 Effects Detected
    1 Positive
    0 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 1

    Sedation 3 of 3 70%

    Adverse Effects 0

    Also reported in combinations. In the 1 Bromazolam report where another drug was taken too, 0 mention hospital, emergency services or an overdose, 1 a seizure and 0 psychosis (too few reports for percentages). In the 3 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to Bromazolam alone, and a mention is not always something that happened to the writer.

    Form / Preparation

    Most common forms and preparations, as a share of the 2 reports that give one

    Too few reports for bars: these forms come from 2 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Liquid 2 of 2

    Legal Status

    Country Status Notes
    United Kingdom Class C Classified as a Class C controlled substance under UK drug control legislation. Class C represents the lowest tier of controlled substances, with possession, supply, and production without authorization constituting criminal offenses.
    United States Unscheduled (federal); Schedule I pending January 2026 Currently unscheduled at the federal level. Pursuant to a Drug Enforcement Administration notice, bromazolam will be placed into Schedule I on January 14, 2026 for two years with a possible one-year extension. Several states, including Virginia, have independently classified bromazolam as Schedule I at the state level, though notably excluding the related analog phenazolam. Despite its current federal unscheduled status, arrests have occurred for mismarketing bromazolam as alprazolam in counterfeit Xanax-shaped tablets, resulting in counterfeit drug charges. The U.S. Department of Justice reported in June 2022 that bromazolam seizures were surging nationwide, frequently detected alongside fentanyl in the illicit drug supply.
    ← Back to Bromazolam